Previous 10 | Next 10 |
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it will report financial re...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that Jim Clemmer, Pres...
AngioDynamics, The PERT Consortium™ and Viz.ai partner on APEX Study to facilitate future enrollment to bring innovative treatment to patients with PE AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring heal...
As a growth investor, the key to building wealth is to buy decent companies in industries with compelling growth stories and hold for the long haul. Due to the launch of new and advanced medical devices to fill unmet needs, few industries will be able to match the growth of the medical ...
AngioDynamics, Inc. (ANGO) Q1 2023 Earnings Conference Call October 6, 2022, 8:00 AM ET Company Participants Jim Clemmer - President and CEO Steve Trowbridge - Executive Vice President and CFO Conference Call Participants Steven Lichtman - Oppenheimer &am...
The following slide deck was published by AngioDynamics, Inc. in conjunction with their 2023 Q1 earnings call. For further details see: AngioDynamics, Inc. 2023 Q1 - Results - Earnings Call Presentation
Shares of small-cap medical technology company AngioDynamics (NASDAQ: ANGO) cratered in morning trading Thursday, falling 12.2% through 10 a.m. ET after missing on earnings this morning. Analysts had forecast that AngioDynamics would lose $0.02 per share ( pro forma ) on...
AngioDynamics press release ( NASDAQ: ANGO ): Q1 Non-GAAP EPS of -$0.06 misses by $0.04 . Revenue of $81.5M (+5.8% Y/Y) misses by $1.93M . Fiscal Year 2023 Financial Guidance: Management is reaffirming its previously issued fiscal year 2023 guidance. Man...
Fiscal Year 2023 First Quarter Highlights Net sales of $81.5 million increased 5.9% compared to the prior-year quarter Med Tech net sales of $22.8 million increased 29.6% Med Device net sales of $58.7 million decreased 1.1% Gross margin of 51....
Summary The hold thesis remains for AngioDynamics following its latest set of numbers and impeding macro-headwinds. Shares have shown high correlation to long-dated treasury yields in FY22 and this continues to drive returns for ANGO. Valuations are unsupportive when stripping...
News, Short Squeeze, Breakout and More Instantly...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that its management is schedule...
Equity Bancshares Inc. Class A (EQBK) is expected to report $0.92 for Q2 2024 Bank of America Corporation (BAC) is expected to report $0.79 for Q2 2024 Aehr Test Systems (AEHR) is expected to report $0.09 for Q4 2024 America Movil S.A.B. de C.V.n Depositary Shares (each representing t...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the fourt...